Загрузка...
Abemaciclib Improves Disease‐Free Survival in High‐Risk HR+/HER2– Early Breast Cancer
Abemaciclib is the first CDK 4/6 inhibitor to show a significant clinical benefit when added to adjuvant endocrine therapy in patients with high‐risk, node‐positive, HR‐positive, HER2‐negative, early‐stage breast cancer, according to findings from the phase III monarchE trial.
Сохранить в:
| Опубликовано в: : | Oncologist |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Inc.
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869338/ https://ncbi.nlm.nih.gov/pubmed/33399254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13665 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|